Trial Profile

Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Futibatinib (Primary)
Indications Cholangiocarcinoma
Focus Therapeutic Use
Acronyms FOENIX-CCA4
Sponsors Taiho Oncology

Most Recent Events

03 Feb 2025 Planned End Date changed from 1 Jun 2026 to 1 Dec 2026.
03 Feb 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Dec 2026.
20 Jan 2024 Study design presented at the 2024 Gastrointestinal Cancers Symposium.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com